Publications

Hathway J, Miller-Wilson L, Yao W, Jensen I, Weinstein M, Parks P. 2021. The health economic impact of varying levels of adherence to colorectal screening on providers and payers. J Med Econ 24(1):69–78; doi: 10.1080/13696998.2020.1858607.

Dean R, Arjunji R, Awano H, Igarash A^, Tanaka A, Jensen IS, Cyr PL et al. Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Miller B, Jensen IS, Dean R, Cyr PL, Slocomb T, James E, Beggs AH. Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS Study. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Miller B, Yao W, Dean R, Jensen I, Cyr PL, Slocomb T. Understanding the impact of XLMTM on parents and caregivers in the US: An analysis of survey results. ISPOR 18^th Annual European Meeting, Milan Italy, 2020.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123.

Dean R, Miller B, Arjunji R, Feltner DE, Sproule DM, Jensen I, Dabbous O. Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan. Abstract PMU36. ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148. ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145.  ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al.  Consequences of increasing mt-sDNA utilization among colorectal cancer screening strategies from a payer perspective. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Health and economic implications for integrated delivery networks of increasing mt-sDNA utilization among colorectal cancer screeners. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.

Hathway J, Jensen IS, Cyr PL, Koshy, TI, Parks, P, Weinstein MC. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US. ISPOR 24th Annual International Meeting, New Orleans LA, 2019

Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019.

Malone D, Miller B, Dean R, Arjunji R, Jensen IS, Maru B, et al. Use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: A United States payer budget impact analysis. ISPOR 2019.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salhuddin K, Prats J, et al. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention (PCI) patients: A US hospital perspective. Transcatheter Cardiovascular Therapeutics (TCT), San Diego, CA, 2018.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of axicabtagene ciloleucel (Axi-cel) in an US population of patients with relapsed or refractory large b-cell lymphoma (RR-LBCL). Podium presentation at ISPOR 23th Annual International Meeting, Baltimore MD, 2018.

Jensen I, Zacherle E, Noone J, Blanchette C, Kay C. Estimating the life-time indirect costs of vision impairment (VI) in inherited retinal degeneration (IRD): Economic impact on education, government benefit programs, productivity and tax loss for patients and caregiver burden. Presented at AAO 2018.

Wu E, Jensen IS, Cyr PL, Kisner H. Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs. American Society of Hematology, Atlanta GA, 2017.